We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 61

Joint public meeting to focus on bridging nanotechnology research

  • Shook Hardy & Bacon LLP
  • -
  • European Union, USA
  • -
  • February 24 2011

The National Nanotechnology Coordination Office has announced that it will spearhead a public meeting to focus on "environmental health and safety questions for nanomaterials and nanotechnology-enabled products" and to "encourage joint US-EU programs of work that would leverage resources."

Updates on international pricing issues for pharmaceutical and biologic products

  • Sidley Austin LLP
  • -
  • China, European Union, France, Germany, United Kingdom, USA
  • -
  • May 18 2012

Sidley Austin LLP’s Global Life Sciences Team is pleased to provide you with this Global Pricing Newsletter, the first in a periodic series updating clients and friends of the firm on pricing issues around the world that may have an impact on pharmaceutical and biologic manufacturers’ legal and business strategies

Transatlantic developments in relation to the antitrust analysis of reverse payment settlements: Lundbeck and Actavis

  • NautaDutilh
  • -
  • European Union, USA
  • -
  • June 21 2013

Lundbeck held various patents relating to citalopram, both in respect of the substance itself and in respect of various production processes. When the

IP challenges for the personalised medicines industry - gene claims (part 1)

  • Barker Brettell LLP
  • -
  • European Union, United Kingdom, USA
  • -
  • May 9 2013

When you go to the doctor you expect to be asked a lot of questions about your symptoms and your lifestyle, as the doctor builds up a clinical

The patentability of stem cells: WARF's success and failure on opposite sides of the Atlantic

  • Shepherd & Wedderburn LLP
  • -
  • European Union, United Kingdom, USA
  • -
  • March 31 2008

The Wisconsin Alumni Research Foundation (WARF) has had three of its patents in relation to stem cells (and in particular, methods of isolation) upheld by the United States Patent and Trademark Office (USPTO

Navigating the evolving regulation and commercialization of stem cell research

  • McDermott Will & Emery
  • -
  • European Union, USA
  • -
  • March 22 2012

Interested parties that can successfully navigate the evolving regulation of stem cell research stand to gain significant scientific and commercial advantage

FDA and European Medicines Agency to do parallel evaluation of new drug marketing applications

  • Hodgson Russ LLP
  • -
  • European Union, USA
  • -
  • April 4 2011

FDA is always criticized and questioned about taking longer to approve regulated products than its counterpart agency in Europe, European Medicines Agency (EMA

Global corporate insurance & regulatory bulletin

  • Mayer Brown JSM
  • -
  • China, European Union, United Kingdom, USA
  • -
  • December 5 2013

The China Insurance Regulatory Commission (“CIRC”) announced new rules (Implementing Rules of Provisional Measures on Outbound Investments with

Measure - Summer 2013

  • King & Spalding LLP
  • -
  • European Union, Middle East, Saudi Arabia, United Arab Emirates, USA
  • -
  • July 3 2013

This issue is rich in news on emerging market trends and legal developments. A revival in real estate investments has been witnessed across the globe

US and European approaches to antibody patents

  • FB Rice
  • -
  • European Union, USA
  • -
  • June 13 2013

When monoclonal antibodies were first produced in 1974, Kohler and Milstein predicted that they “could be valuable for medical and industrial use”